Overview
To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.
Description
Primary Objectives
-To determine the incidence of protocol specified pre-surgery MRD-positivity in IBC (assessment between completion of planned systemic therapy and surgery).
Secondary Objectives
- To establish the feasibility of multi-institutional MRD data collection using standard of care Signatera analysis in IBC participants.
- To evaluate the association of pre-surgery MRD to pathologic response.
- To evaluate participant reported QOL for worry about recurrence based in participants receiving MRD results
- To establish protocol-optional baseline and longitudinal MRD data collection in IBC participants and report the frequency of MRD longitudinally
- To determine the median lead time between the first MRD-positive result and clinical recurrence.
- To determine whether adjuvant therapies decrease the amount of MRD in participants, and the association with relapse.
Eligibility
Inclusion Criteria:
- Female or males ≥18 years of age with the ability to understand and sign a written
- Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
- Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
- Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
- Participants must be English-speaking.
Exclusion Criteria:
-